Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new anticoagulant, despite missing efficacy targets in two mid-stage studies. The OCEANIC trial ...

Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded the novel anticoagulant ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

USA: A recent subgroup analysis from the OCEANIC-AF randomized clinical trial highlights that asundexian, a novel oral Factor XIa inhibitor, may offer a favorable balance of safety and efficacy ...

Roundup’s time may be up.

1. Recurrent VTE occurred in 2.1% in the reduced-dose group and 2.8% in the full-dose group, with HR 0.76 (was noninferior). 2. Clinically relevant bleeding occurred in 12.1% in the reduced-dose group ...